Edition:
United Kingdom

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

1.50USD
20 Apr 2018
Change (% chg)

$-0.05 (-3.23%)
Prev Close
$1.55
Open
$1.50
Day's High
$1.50
Day's Low
$1.50
Volume
707
Avg. Vol
9,673
52-wk High
$2.95
52-wk Low
$1.25

Chart for

About

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial... (more)

Overall

Beta: --
Market Cap(Mil.): $70.64
Shares Outstanding(Mil.): 24.36
Dividend: --
Yield (%): --

Financials

  CHMA.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.28 -- --
ROI: -34.47 14.84 14.38
ROE: -35.41 16.34 16.07

BRIEF-Chiasma Inc Files For Mixed Shelf Of Up To $100 Million ‍​

* CHIASMA INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING‍​ Source text: (https://bit.ly/2DLHB1V) Further company coverage:

22 Mar 2018

BRIEF-Chiasma Q4 Loss Per Share $0.25

* ‍EXPECTS TO HAVE A CASH AND INVESTMENT BALANCE OF AT LEAST $35 MILLION AT END OF 2018​ Source text for Eikon: Further company coverage:

20 Mar 2018

BRIEF-Chiasma Announces Expected Year-End 2017 Cash And Investments Balance Of About $67 Mln

* CHIASMA INC - ANNOUNCES EXPECTED YEAR-END 2017 CASH AND INVESTMENTS BALANCE OF APPROXIMATELY $67 MILLION

08 Jan 2018

BRIEF-Chiasma Q3 loss per share $0.28

* Chiasma Inc - ‍ cash, cash equivalents & marketable securities as of Sept 30, 2017 were $73.2 million, compared with $93.0 million as of December 31, 2016​ Source text for Eikon: Further company coverage:

09 Nov 2017

Earnings vs. Estimates